PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
11.87%
Revenue growth similar to META's 11.10%. Walter Schloss would see if both companies share industry tailwinds.
14.23%
Gross profit growth 1.25-1.5x META's 12.54%. Bruce Berkowitz would see if strategic sourcing or brand premium explains outperformance.
17.79%
EBIT growth above 1.5x META's 8.69%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
17.79%
Operating income growth above 1.5x META's 8.69%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
3.32%
Net income growth under 50% of META's 9.45%. Michael Burry would suspect the firm is falling well behind a key competitor.
3.76%
EPS growth under 50% of META's 9.88%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
3.82%
Diluted EPS growth under 50% of META's 9.39%. Michael Burry would worry about an eroding competitive position or excessive dilution.
-0.63%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.36%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
13.48%
OCF growth above 1.5x META's 8.20%. David Dodd would confirm a clear edge in underlying cash generation.
22.83%
FCF growth above 1.5x META's 8.33%. David Dodd would verify if the firm’s strategic investments yield superior returns.
560.46%
10Y revenue/share CAGR under 50% of META's 2673.42%. Michael Burry would suspect a lasting competitive disadvantage.
195.12%
5Y revenue/share CAGR at 50-75% of META's 357.29%. Martin Whitman would worry about a lagging mid-term growth trajectory.
96.74%
3Y revenue/share CAGR at 75-90% of META's 123.81%. Bill Ackman would expect new product strategies to close the gap.
499.27%
10Y OCF/share CAGR under 50% of META's 8665.64%. Michael Burry would worry about a persistent underperformance in cash creation.
146.11%
Below 50% of META's 319.24%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
124.32%
3Y OCF/share CAGR similar to META's 114.16%. Walter Schloss might see both benefiting from a rising tide or parallel expansions.
612.43%
Below 50% of META's 3597.09%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
289.48%
5Y net income/share CAGR at 75-90% of META's 362.24%. Bill Ackman would advocate improvements to match competitor’s profit expansion.
502.01%
3Y net income/share CAGR above 1.5x META's 107.31%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
340.20%
Equity/share CAGR of 340.20% while META is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
90.49%
5Y equity/share CAGR at 50-75% of META's 177.69%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
52.26%
3Y equity/share CAGR at 50-75% of META's 77.34%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.27%
AR growth well above META's 13.84%. Michael Burry fears inflated revenue or higher default risk in the near future.
2.14%
Inventory growth of 2.14% while META is zero. Bruce Berkowitz wonders if we anticipate a new wave of demand or risk being stuck with extra product.
2.54%
Asset growth at 50-75% of META's 4.33%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
3.94%
1.25-1.5x META's 3.45%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
2.68%
Debt growth far above META's 3.38%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
2.54%
R&D dropping or stable vs. META's 17.30%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
18.22%
SG&A growth well above META's 16.80%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.